State of New Jersey Common Pension Fund D Reduces Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

State of New Jersey Common Pension Fund D lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 24.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,225 shares of the biopharmaceutical company’s stock after selling 1,665 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Madrigal Pharmaceuticals were worth $2,396,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Chicago Partners Investment Group LLC grew its position in Madrigal Pharmaceuticals by 16.0% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 969 shares of the biopharmaceutical company’s stock worth $297,000 after purchasing an additional 134 shares during the last quarter. AlphaQuest LLC lifted its stake in shares of Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 66 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth $428,000. Teacher Retirement System of Texas grew its holdings in shares of Madrigal Pharmaceuticals by 9.6% during the second quarter. Teacher Retirement System of Texas now owns 3,860 shares of the biopharmaceutical company’s stock valued at $1,168,000 after buying an additional 338 shares during the last quarter. Finally, Emerald Advisers LLC grew its holdings in shares of Madrigal Pharmaceuticals by 10.9% during the second quarter. Emerald Advisers LLC now owns 53,108 shares of the biopharmaceutical company’s stock valued at $16,073,000 after buying an additional 5,199 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Stock Down 0.4%

Shares of MDGL opened at $435.01 on Friday. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of -33.80, a PEG ratio of 6.18 and a beta of -1.01. Madrigal Pharmaceuticals, Inc. has a 52 week low of $265.00 and a 52 week high of $615.00. The stock’s 50-day moving average price is $521.61 and its 200-day moving average price is $482.31. The company has a quick ratio of 3.26, a current ratio of 3.44 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 42.55%. The company had revenue of $321.08 million during the quarter, compared to analyst estimates of $310.36 million. During the same period in the previous year, the firm posted ($2.71) earnings per share. The company’s revenue was up 210.8% compared to the same quarter last year. On average, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Insider Transactions at Madrigal Pharmaceuticals

In related news, CEO William John Sibold sold 2,400 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $575.34, for a total transaction of $1,380,816.00. Following the sale, the chief executive officer directly owned 150,074 shares of the company’s stock, valued at approximately $86,343,575.16. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Rebecca Taub sold 18,650 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $552.15, for a total transaction of $10,297,597.50. Following the completion of the transaction, the director directly owned 461,044 shares of the company’s stock, valued at $254,565,444.60. The trade was a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 99,537 shares of company stock worth $53,485,702. Insiders own 21.50% of the company’s stock.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra commercial strength: Q4 net sales of roughly $321.1M (Q4) and $958.4M for full‑year 2025, more than 36,250 patients on therapy and nearly $989M in cash and marketable securities — evidence of strong revenue growth and a sizeable cash runway. Press Release
• Neutral Sentiment: Investor materials and transparency: company provided an earnings slide deck and held a conference call — useful for modeling future margins, guidance and pipeline milestones. Earnings Presentation
• Negative Sentiment: Large EPS miss and rising expenses: reported Q4 EPS of ($2.57) vs. consensus ~$0.04, driven by a wider loss as expenses surged despite revenue beating estimates — this prompted an immediate negative market reaction. Zacks Article
• Negative Sentiment: Analyst action: Bank of America cut its price target (from $570 to $529) and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure. Benzinga

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MDGL. B. Riley Financial raised their target price on Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. HC Wainwright increased their price objective on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the company a “buy” rating in a report on Friday, November 21st. The Goldman Sachs Group restated a “buy” rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. Truist Financial upped their target price on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Finally, Zacks Research downgraded shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $669.86.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.